https://www.selleckchem.com/pr....oducts/puromycin-ami
Over the course of 4 years of treatment, the prescription rate of L-dopa monotherapy and non-ergot DA monotherapy decreased by 63.7% and 44.1%, respectively, whereas that of L-dopa and non-ergot DA combination therapy increased by 103.7%. Combination therapy with L-dopa, non-ergot DA, and monoamine oxidase-B inhibitors was gradually increased at a later stage. CONCLUSION These results highlight that the state of PD treatment in Japan adheres to most of the recommendations in the 2011 national guidelines, but also prece
Like
Comment
Share
